Prelude Capital Management, LLC Cerus Corp Transaction History

Prelude Capital Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$2.65 - $3.81 $2,024 - $2,910	764 Added 7.25%	11,304 $33,000
Q4 2022 Feb 14, 2023	SELL	$3.38 - $4.22 $32,867 - $41,035	-9,724 Reduced 47.99%	10,540 $38,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.83 $15,246 - $25,914	4,445 Added 28.1%	20,264 $73,000
Q2 2022 Aug 15, 2022	SELL	$4.41 - $5.69 $35,549 - $45,867	-8,061 Reduced 33.76%	15,819 $84,000
Q1 2022 May 16, 2022	BUY	$4.81 - $6.99 $114,862 - $166,921	23,880 New	23,880 $131,000
Q4 2020 Feb 16, 2021	SELL	$5.25 - $8.56 $3,675 - $5,992	-700 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$5.78 - $7.47 $4,046 - $5,229	700 New	700 $4,000
Q2 2019 Aug 14, 2019	SELL	$4.51 - $6.6 $468,607 - $685,766	-103,904 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$4.89 - $7.16 $123,095 - $180,238	25,173 Added 31.97%	103,904 $527,000
Q3 2018 Nov 14, 2018	SELL	$6.89 - $7.78 $31,005 - $35,010	-4,500 Reduced 5.41%	78,731 $568,000
Q2 2018 Aug 14, 2018	BUY	$5.19 - $7.25 $51,458 - $71,883	9,915 Added 13.52%	83,231 $555,000
Q1 2018 May 15, 2018	BUY	$3.56 - $5.74 $261,004 - $420,833	73,316 New	73,316 $402,000

157

148M

84.2K

55.5K

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $321M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.